Quantum Biopharma Ltd. Class B Subordinate Voting Shares
4.35
USD
Sponsored
-0.33
-6.98%
Mar 25, 16:00 UTC -4
Closed
Pre-Market
3.94
-0.41
-9.43%
QNTM Earnings Reports
Positive Surprise Ratio
QNTM beat 2 of 5 last estimates.
40%
Next Report
In 3 Days
Date of Next Report
Mar 26, 2026
Estimate forQ4 25(Revenue/ EPS)
--
/
--
Implied change fromQ-- --(Revenue/ EPS)
--
/
--
Implied change fromQ4 24(Revenue/ EPS)
--
/
--
Quantum Biopharma Ltd. Class B Subordinate Voting Shares earnings per share and revenue
On --, QNTM reported earnings of -- USD per share (EPS) for -- --, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to Q4 25, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
BioCardia, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.17
Actual
-$0.06
Surprise
+65.40%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
FAQ
What were Quantum Biopharma Ltd. Class B Subordinate Voting Shares's earnings and revenue for the latest quarter Q-- --?
For Q-- --, Quantum Biopharma Ltd. Class B Subordinate Voting Shares reported EPS of --, Inline estimates by --, and revenue of --, -- -- expectations.
How did the market react to Quantum Biopharma Ltd. Class B Subordinate Voting Shares's Q-- -- earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Quantum Biopharma Ltd. Class B Subordinate Voting Shares expected to report next?
The next earning report is scheduled for Mar 26, 2026.
What are the forecasts for Quantum Biopharma Ltd. Class B Subordinate Voting Shares's next earnings report?
Based on --
analysts, Quantum Biopharma Ltd. Class B Subordinate Voting Shares is expected to report EPS of -- and revenue of -- for Q4 2025.